Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials (Q79345406)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17096017%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

title

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17096017%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

main subject

phase II clinical trial

1 reference

6

Stadtmauer EA

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17096017%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

Jagannath S

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17096017%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Richardson PG

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17096017%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Sonneveld P

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17096017%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Schuster MW

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17096017%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Irwin D

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17096017%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Facon T

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17096017%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Harousseau JL

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17096017%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Cowan JM

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17096017%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Anderson KC

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17096017%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

publication date

9 November 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17096017%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17096017%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17096017%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17096017%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

151-157

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17096017%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404442

21 December 2019

exact match

0 references

cites work

Prognostic value of cytogenetics in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Chromosome 13 deletion/hypodiploidy and prognosis in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

The ubiquitin-proteasome pathway and its role in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

International staging system for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Cytogenetic Abnormalities Correlate with the Plasma Cell Labeling Index and Extent of Bone Marrow Involvement in Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Determination of chromosome 13 status in bone marrow cells of patients with multiple myeloma using combined morphologic and fluorescence in situ hybridization analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Bortezomib in combination with dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Graft versus myeloma may overcome the unfavorable effect of deletion of chromosome 13 in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404442

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404442

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17096017%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

21 December 2019

1030328715

0 references

Fatcat ID

release_vy55t2xuzzdi3ks7xqfr4ze2sm

0 references

1 reference